NEW YORK, Nov. 9, 2022 /PRNewswire/ -- The "Anaplastic Thyroid Cancer Drugs Market by Product and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. The report expects the market size to grow by USD 230.53 million, accelerating at a CAGR of 5.44% during the forecast period. The global anaplastic thyroid cancer drugs market is fragmented with more than 20 companies and various types of branded drugs and generics of some chemotherapeutics. The competition is high among vendors owing to the introduction of novel therapies in the market. Also, the presence of a strong pipeline of drugs used for treating anaplastic thyroid cancer will further intensify the competition during the forecast period. Furthermore, the market will witness the approvals of some drugs during the forecast period, which will intensify the competition among vendors. Get deeper insights into the vendor landscape and make informed decisions. Buy Report Now!
With a focus on identifying dominant industry influencers, Technavio's reports present a detailed study by the way of synthesis, and summation of data from multiple sources. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.
- Anaplastic Thyroid Cancer Drugs Market Size
- Anaplastic Thyroid Cancer Drugs Market Trends
- Anaplastic Thyroid Cancer Drugs Market Industry Analysis
- Product
- Chemotherapy
- Novel Therapy
The market growth will be significant in the chemotherapy segment during the forecast period. The growth of the chemotherapy segment can be mainly attributed to the high prevalence of thyroid cancer and chemotherapy being the second-line treatment for anaplastic thyroid cancer after surgery. The incidence rate of thyroid cancer is increasing at a significant rate, almost increasing threefold every ten years. Although the majority of thyroid tumors are curable, about 2%-3% of thyroid cancers are refractory to standard treatments. These types include undifferentiated, highly aggressive, and mostly chemo-resistant tumors and are known as anaplastic thyroid cancer.
- Geography
- North America
- Europe
- Asia
- Rest Of World (ROW)
37% of the market growth will come from North America during the forecast period. The market growth in North America is primarily attributed to the increased cases of thyroid cancer in the region. The increasing geriatric population in the region is another factor propelling the growth of the anaplastic thyroid cancer drugs market in North America.
Identify other potential segments and regions in the market. Download Free Sample Report
Some of the major vendors of the anaplastic thyroid cancer drugs market in l4 industry include Akorn Inc., Amneal Pharmaceuticals Inc., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Exelixis Inc., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Medtronic Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc.
To help businesses improve their market position, Technavio's report provides a detailed analysis of around 25 vendors operating in the market. Backed with competitive intelligence and benchmarking, our research report on the anaplastic thyroid cancer drugs market is designed to provide entry support, customer profile, & M&As as well as go-to-market strategy support.
The High prevalence of thyroid cancer, the introduction of targeted therapies, and the rising geriatric population will offer immense growth opportunities. To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments while maintaining their positions in the slow-growing segments.
Technavio's library includes over 17,000+ reports covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to our Technavio Insights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist anaplastic thyroid cancer drugs market growth during the next five years
- Estimation of the anaplastic thyroid cancer drugs market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the anaplastic thyroid cancer drugs market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of anaplastic thyroid cancer drugs market vendors
- The BRAF kinase inhibitors market share is expected to accelerate at a CAGR of 7.73%, and reach an estimated value of USD 1.19 billion by 2026. The high target affinity and specificity of BRAF kinase inhibitors is notably driving the BRAF kinase inhibitors market growth, although factors such as the availability of substitute therapies may impede the market growth.
- The cancer biologics market share is expected to increase by USD 34.97 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.91%. The rising global incidence of cancer is notably driving the cancer biologics market growth, although factors such as the high cost of cancer biologics may impede market growth.
Anaplastic Thyroid Cancer Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.44% |
Market growth 2022-2026 |
USD 230.53 million |
Market structure |
Fragmented |
YoY growth (%) |
4.29 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 37% |
Key consumer countries |
US, Canada, Italy, China, and India |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Akorn Inc., Amneal Pharmaceuticals Inc., Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Exelixis Inc., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Medtronic Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Product
- 5.1 Market segments
- Exhibit 24: Chart on Product - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
- 5.2 Comparison by Product
- Exhibit 26: Chart on Comparison by Product
- Exhibit 27: Data Table on Comparison by Product
- 5.3 Chemotherapy - Market size and forecast 2021-2026
- Exhibit 28: Chart on Chemotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Chemotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Chemotherapy - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Chemotherapy - Year-over-year growth 2021-2026 (%)
- 5.4 Novel therapy - Market size and forecast 2021-2026
- Exhibit 32: Chart on Novel therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Novel therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Novel therapy - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Novel therapy - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Product
- Exhibit 36: Market opportunity by Product ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Italy - Market size and forecast 2021-2026
- Exhibit 62: Chart on Italy - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Italy - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Italy - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Italy - Year-over-year growth 2021-2026 (%)
- 7.9 China - Market size and forecast 2021-2026
- Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 India - Market size and forecast 2021-2026
- Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Bayer AG
- Exhibit 85: Bayer AG - Overview
- Exhibit 86: Bayer AG - Business segments
- Exhibit 87: Bayer AG - Key offerings
- Exhibit 88: Bayer AG - Segment focus
- 10.4 Bristol Myers Squibb Co.
- Exhibit 89: Bristol Myers Squibb Co. - Overview
- Exhibit 90: Bristol Myers Squibb Co. - Product / Service
- Exhibit 91: Bristol Myers Squibb Co. - Key offerings
- 10.5 Eisai Co. Ltd.
- Exhibit 92: Eisai Co. Ltd. - Overview
- Exhibit 93: Eisai Co. Ltd. - Business segments
- Exhibit 94: Eisai Co. Ltd. - Key offerings
- Exhibit 95: Eisai Co. Ltd. - Segment focus
- 10.6 Johnson and Johnson
- Exhibit 96: Johnson and Johnson - Overview
- Exhibit 97: Johnson and Johnson - Business segments
- Exhibit 98: Johnson and Johnson - Key news
- Exhibit 99: Johnson and Johnson - Key offerings
- Exhibit 100: Johnson and Johnson - Segment focus
- 10.7 Medtronic Plc
- Exhibit 101: Medtronic Plc - Overview
- Exhibit 102: Medtronic Plc - Business segments
- Exhibit 103: Medtronic Plc - Key news
- Exhibit 104: Medtronic Plc - Key offerings
- Exhibit 105: Medtronic Plc - Segment focus
- 10.8 Merck KGaA
- Exhibit 106: Merck KGaA - Overview
- Exhibit 107: Merck KGaA - Business segments
- Exhibit 108: Merck KGaA - Key news
- Exhibit 109: Merck KGaA - Key offerings
- Exhibit 110: Merck KGaA - Segment focus
- 10.9 Novartis AG
- Exhibit 111: Novartis AG - Overview
- Exhibit 112: Novartis AG - Business segments
- Exhibit 113: Novartis AG - Key offerings
- Exhibit 114: Novartis AG - Segment focus
- 10.10 Pfizer Inc.
- Exhibit 115: Pfizer Inc. - Overview
- Exhibit 116: Pfizer Inc. - Product / Service
- Exhibit 117: Pfizer Inc. - Key news
- Exhibit 118: Pfizer Inc. - Key offerings
- 10.11 Takeda Pharmaceutical Co. Ltd.
- Exhibit 119: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 120: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 121: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 122: Takeda Pharmaceutical Co. Ltd. - Key offerings
- 10.12 Viatris Inc.
- Exhibit 123: Viatris Inc. - Overview
- Exhibit 124: Viatris Inc. - Business segments
- Exhibit 125: Viatris Inc. - Key offerings
- Exhibit 126: Viatris Inc. - Segment focus
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 127: Inclusions checklist
- Exhibit 128: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 129: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 130: Research methodology
- Exhibit 131: Validation techniques employed for market sizing
- Exhibit 132: Information sources
- 11.5 List of abbreviations
- Exhibit 133: List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article